2025 Q3 -tulosraportti
94 päivää sitten1 t 0 min
Tarjoustasot
Määrä
Osto
1 332
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
27,77VWAP
Alin
22,95VaihtoMäärä
961,4 67 308 353
VWAP
Ylin
27,77Alin
22,95VaihtoMäärä
961,4 67 308 353
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenA fledgling attempt to bring a dying stock back to life, or maybe just a board that was supposed to unload the last shares before closing time - They could probably figure out that it would secure them a huge lawsuit! But, I wonder if they're closed before then😂 The fall certainly doesn't stop!
·2 t sittenThe rhetoric in this comment thread is getting quite harsh. Many seem to believe that everything Hims & Hers does is illegal, despite the fact that – as far as I know – there is no court ruling establishing this. In the USA, compounding is legal under specific circumstances. Typically in two cases: Shortage: When the original medicine is on the FDA’s official list of drugs in short supply (semaglutide has been removed from this list now). Patient need: When a patient requires a specific customization (e.g., a particular dose or a product without a certain excipient) that is not available in the commercial product. It is primarily under 'patient need' that Hims operates. It is a legal gray area, granted, but compounding is a legal practice in the USA. To be so certain and call it a 'rogue company' is, in my opinion, not factually founded. I understand the frustration as a Novo shareholder if one feels they are taking market share, but instead of slandering the company, the anger should perhaps rather be directed at the American legislation that enables this :3 as of today (5. Feb 2026) Novo has filed a lawsuit against Hims & Hers. Then we'll see how it all turns out. Happy little Friday, and watch out for slippery roads 🫡
·2 t sittenI understand the argument that compounding can be legal in the USA. But that's precisely the point: only under very narrow conditions. Novo's case is strong because Hims & Hers hardly operates within the framework of legitimate patient-specific compounding. When a standardized semaglutide solution is offered on a large scale, marketed broadly to a general target group, one moves away from individual customization and into something resembling unauthorized mass production of an unapproved drug. That is precisely what FDA regulations seek to prevent. Furthermore, semaglutide is no longer on the FDA's shortage list. Thus, one of the most important legal bases for compounding falls away. When a fully FDA-approved alternative is available, it becomes difficult to argue that parallel production is necessary for the sake of patients. Finally, the case is not only about compounding, but also about patents, formulation, and circumvention of the approval process. Compounding does not give carte blanche to copy a patented product and compete directly with it without FDA approval. So yes — compounding is legal in principle. But there is much to suggest that Novo will indeed be able to prove that Hims & Hers has moved outside the legal grey area and into regular violation. That is why this case is more than just “big pharma vs. startup” — and why Novo can absolutely end up winning.
·4 t sittenIt is downright dangerous to use Hims' copy product. Furthermore, there are formulas and technical characteristics of the pill that cannot be copied, so be careful about buying the copy version.
·4 t sitten · Muokattubuying a ticket...long time since last
·5 t sittenNOVO announces a lawsuit against HIMS. Copying others' medicines will probably not lead to anything good, HIMS is in trouble. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916489
·4 t sittenI really hope they get slaughtered in court.. It simply cannot be right that one has to spend billions of kroner to invent a product that is almost copied on. Launch day. Good to see the price trickling down on hims. They don't deserve to profit from Novo's product- ·5 t sittenNovo Nordisk has strong patent rights for Wegovy (semaglutide) in the USA and Europe, running until 2031-2032, and has had a pill version approved. Hims & Hers cannot legally sell copies of Wegovy, as US courts have stopped the production of copy products, and the FDA warns against unauthorized versions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
94 päivää sitten1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenA fledgling attempt to bring a dying stock back to life, or maybe just a board that was supposed to unload the last shares before closing time - They could probably figure out that it would secure them a huge lawsuit! But, I wonder if they're closed before then😂 The fall certainly doesn't stop!
- ·2 t sittenThe rhetoric in this comment thread is getting quite harsh. Many seem to believe that everything Hims & Hers does is illegal, despite the fact that – as far as I know – there is no court ruling establishing this. In the USA, compounding is legal under specific circumstances. Typically in two cases: Shortage: When the original medicine is on the FDA’s official list of drugs in short supply (semaglutide has been removed from this list now). Patient need: When a patient requires a specific customization (e.g., a particular dose or a product without a certain excipient) that is not available in the commercial product. It is primarily under 'patient need' that Hims operates. It is a legal gray area, granted, but compounding is a legal practice in the USA. To be so certain and call it a 'rogue company' is, in my opinion, not factually founded. I understand the frustration as a Novo shareholder if one feels they are taking market share, but instead of slandering the company, the anger should perhaps rather be directed at the American legislation that enables this :3 as of today (5. Feb 2026) Novo has filed a lawsuit against Hims & Hers. Then we'll see how it all turns out. Happy little Friday, and watch out for slippery roads 🫡·2 t sittenI understand the argument that compounding can be legal in the USA. But that's precisely the point: only under very narrow conditions. Novo's case is strong because Hims & Hers hardly operates within the framework of legitimate patient-specific compounding. When a standardized semaglutide solution is offered on a large scale, marketed broadly to a general target group, one moves away from individual customization and into something resembling unauthorized mass production of an unapproved drug. That is precisely what FDA regulations seek to prevent. Furthermore, semaglutide is no longer on the FDA's shortage list. Thus, one of the most important legal bases for compounding falls away. When a fully FDA-approved alternative is available, it becomes difficult to argue that parallel production is necessary for the sake of patients. Finally, the case is not only about compounding, but also about patents, formulation, and circumvention of the approval process. Compounding does not give carte blanche to copy a patented product and compete directly with it without FDA approval. So yes — compounding is legal in principle. But there is much to suggest that Novo will indeed be able to prove that Hims & Hers has moved outside the legal grey area and into regular violation. That is why this case is more than just “big pharma vs. startup” — and why Novo can absolutely end up winning.
- ·4 t sittenIt is downright dangerous to use Hims' copy product. Furthermore, there are formulas and technical characteristics of the pill that cannot be copied, so be careful about buying the copy version.·4 t sitten · Muokattubuying a ticket...long time since last
- ·5 t sittenNOVO announces a lawsuit against HIMS. Copying others' medicines will probably not lead to anything good, HIMS is in trouble. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916489·4 t sittenI really hope they get slaughtered in court.. It simply cannot be right that one has to spend billions of kroner to invent a product that is almost copied on. Launch day. Good to see the price trickling down on hims. They don't deserve to profit from Novo's product
- ·5 t sittenNovo Nordisk has strong patent rights for Wegovy (semaglutide) in the USA and Europe, running until 2031-2032, and has had a pill version approved. Hims & Hers cannot legally sell copies of Wegovy, as US courts have stopped the production of copy products, and the FDA warns against unauthorized versions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 332
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
27,77VWAP
Alin
22,95VaihtoMäärä
961,4 67 308 353
VWAP
Ylin
27,77Alin
22,95VaihtoMäärä
961,4 67 308 353
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
2025 Q3 -tulosraportti
94 päivää sitten1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenA fledgling attempt to bring a dying stock back to life, or maybe just a board that was supposed to unload the last shares before closing time - They could probably figure out that it would secure them a huge lawsuit! But, I wonder if they're closed before then😂 The fall certainly doesn't stop!
- ·2 t sittenThe rhetoric in this comment thread is getting quite harsh. Many seem to believe that everything Hims & Hers does is illegal, despite the fact that – as far as I know – there is no court ruling establishing this. In the USA, compounding is legal under specific circumstances. Typically in two cases: Shortage: When the original medicine is on the FDA’s official list of drugs in short supply (semaglutide has been removed from this list now). Patient need: When a patient requires a specific customization (e.g., a particular dose or a product without a certain excipient) that is not available in the commercial product. It is primarily under 'patient need' that Hims operates. It is a legal gray area, granted, but compounding is a legal practice in the USA. To be so certain and call it a 'rogue company' is, in my opinion, not factually founded. I understand the frustration as a Novo shareholder if one feels they are taking market share, but instead of slandering the company, the anger should perhaps rather be directed at the American legislation that enables this :3 as of today (5. Feb 2026) Novo has filed a lawsuit against Hims & Hers. Then we'll see how it all turns out. Happy little Friday, and watch out for slippery roads 🫡·2 t sittenI understand the argument that compounding can be legal in the USA. But that's precisely the point: only under very narrow conditions. Novo's case is strong because Hims & Hers hardly operates within the framework of legitimate patient-specific compounding. When a standardized semaglutide solution is offered on a large scale, marketed broadly to a general target group, one moves away from individual customization and into something resembling unauthorized mass production of an unapproved drug. That is precisely what FDA regulations seek to prevent. Furthermore, semaglutide is no longer on the FDA's shortage list. Thus, one of the most important legal bases for compounding falls away. When a fully FDA-approved alternative is available, it becomes difficult to argue that parallel production is necessary for the sake of patients. Finally, the case is not only about compounding, but also about patents, formulation, and circumvention of the approval process. Compounding does not give carte blanche to copy a patented product and compete directly with it without FDA approval. So yes — compounding is legal in principle. But there is much to suggest that Novo will indeed be able to prove that Hims & Hers has moved outside the legal grey area and into regular violation. That is why this case is more than just “big pharma vs. startup” — and why Novo can absolutely end up winning.
- ·4 t sittenIt is downright dangerous to use Hims' copy product. Furthermore, there are formulas and technical characteristics of the pill that cannot be copied, so be careful about buying the copy version.·4 t sitten · Muokattubuying a ticket...long time since last
- ·5 t sittenNOVO announces a lawsuit against HIMS. Copying others' medicines will probably not lead to anything good, HIMS is in trouble. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916489·4 t sittenI really hope they get slaughtered in court.. It simply cannot be right that one has to spend billions of kroner to invent a product that is almost copied on. Launch day. Good to see the price trickling down on hims. They don't deserve to profit from Novo's product
- ·5 t sittenNovo Nordisk has strong patent rights for Wegovy (semaglutide) in the USA and Europe, running until 2031-2032, and has had a pill version approved. Hims & Hers cannot legally sell copies of Wegovy, as US courts have stopped the production of copy products, and the FDA warns against unauthorized versions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 332
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
27,77VWAP
Alin
22,95VaihtoMäärä
961,4 67 308 353
VWAP
Ylin
27,77Alin
22,95VaihtoMäärä
961,4 67 308 353
Välittäjätilasto
Dataa ei löytynyt